	FORM	4 U		TES SE		IES /			ANGE	ECOM	MIS	SION			
to Section 16. Form 4 or Form 5 obligations may continue. See				IT OF CHANGES IN BENEFICIAL OWNI pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							RSHIP OMB Estim		OMB Nu Estimate	IB APPRO mber: d average burd r response:	3235-0287
1. Name and Address of Reporting Person <sup>*</sup> <u>Tatsis Ourania</u>				2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [ VRTX ]								tionship of Re all applicable Director Officer (give below)	give title C		s) to Issuer D% Owner ther (specify elow)
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED				3. Date of Earliest Transaction (Month/Day/Year) 02/17/2023								,	f Reg. (	& Quality O	
50 NOR (Street) BOSTO	THERN AV	2210	4. If Ame	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(St		Zip)					Diamagad	<u></u>	Denefie	i a lla d	Ourned			
Table I - Non-Deriva   1. Title of Security (Instr. 3)   2. Transaction Date (Month/Day/Yea)			2A. De Execut ar) if any	2A. Deemed Execution Date,		eu, i action Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				5. Amount of Securities Beneficially Owned Followin Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price		Transaction( (Instr. 3 and 4	s) (`	iiisu. 4)	(1150.4)
Common Stock			02/17/202	3		F		4,498	D	\$292.8	35	60,947	'	D	
Common Stock			02/21/202	3				4	D	\$291.0	01	60,943		D	
Common Stock			02/21/202	3				145	D	\$292.85	(2)(3)	60,798		D	
Common Stock			02/21/202	3		<b>S</b> <sup>(1)</sup>		207	D	\$293.83	(2)(4)	60,591		D	
Common Stock			02/21/202	3		<b>S</b> <sup>(1)</sup>		124	D	\$294.77	(2)(5)	60,467		D	
		Та	ble II - Derivat (e.g., pւ					isposed o s, conver				wned			
1	2.	3. Transaction	3A. Deemed	4.	5. Numi n of			xercisable an		itle and ount of			mber of ative	10. Ownership	11. Nature of Indirec

Explanation of Responses:

1. Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.

2. Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(D)

(A)

٧

Code

Date Exercisable Expiration Date

3. Open market sales reported on this line occurred at a weighted average price of \$292.85 (range \$292.37 to \$293.36).

4. Open market sales reported on this line occurred at a weighted average price of \$293.83 (range \$293.39 to \$294.38).

5. Open market sales reported on this line occurred at a weighted average price of \$294.77 (range \$294.42 to \$295.37).

Remarks:

## <u>/s/ Christiana Stevenson,</u> <u>Attorney-in-Fact</u>

Amount or Number

of Shares

Title

02/22/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.